Rockwell Medical (NASDAQ:RMTI) Issues Earnings Results

Rockwell Medical (NASDAQ:RMTI) announced its earnings results on Thursday. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.20, FiscalAI reports. Rockwell Medical had a negative return on equity of 15.41% and a negative net margin of 7.98%.The business had revenue of $17.78 million during the quarter, compared to analyst estimates of $17.82 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Second-quarter net sales rose 11% year over year to $17.8 million, driven by new Western U.S. customers, higher purchasing from existing customers, and pricing actions. Management said it remains on track for 2026 sales guidance of $70 million to $75 million.
• Gross margin expanded to 18% from 16% a year ago, while gross profit increased 30% to $3.2 million. The company attributed the improvement to lower manufacturing costs, automation, higher volumes, and operational efficiencies, and reiterated its full-year gross-margin target of 18% to 22%.
• Rockwell generated approximately $2.1 million in operating cash flow during the quarter and ended June with $24.8 million in cash and available-for-sale investments. Management reiterated expectations for positive operating cash flow and adjusted EBITDA of $1 million to $2 million in 2026.
• Expansion in the Western U.S. is gaining traction, with incremental volume carrying margins above the company average and liquid products representing a larger share of the regional mix. New and renewed customer agreements, generally structured for about three years with pricing escalators, are also increasing revenue visibility.
• The company is evaluating a complementary renal-care medical device that could address a sizable market and potentially face limited U.S. competition. Development remains early-stage, with investment funded from the existing balance sheet and no additional capital raise currently planned.

Rockwell Medical Stock Performance

Shares of NASDAQ:RMTI traded up $0.31 during trading on Thursday, hitting $7.82. 81,208 shares of the company were exchanged, compared to its average volume of 32,157. The stock has a 50 day moving average of $6.46 and a 200 day moving average of $8.23. The company has a market cap of $31.05 million, a PE ratio of -5.21 and a beta of 1.60. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.74 and a quick ratio of 3.43. Rockwell Medical has a 52-week low of $4.89 and a 52-week high of $21.00.

Institutional Investors Weigh In On Rockwell Medical

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC grew its holdings in shares of Rockwell Medical by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares during the last quarter. Vanguard Group Inc. lifted its stake in Rockwell Medical by 12.3% in the third quarter. Vanguard Group Inc. now owns 1,354,147 shares of the company’s stock worth $1,625,000 after purchasing an additional 148,737 shares during the last quarter. Jane Street Group LLC purchased a new stake in Rockwell Medical during the fourth quarter valued at about $84,000. Finally, XTX Topco Ltd grew its stake in shares of Rockwell Medical by 286.5% during the fourth quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock valued at $52,000 after buying an additional 46,029 shares during the last quarter. 23.31% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RMTI has been the topic of several research analyst reports. Weiss Ratings upgraded Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 6th. Wall Street Zen raised Rockwell Medical to a “hold” rating in a report on Saturday, July 25th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price (up from $2.00) on shares of Rockwell Medical in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $20.00.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.